Activated Charcoal Arsenic Triiodide Oenanthe Aqua
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Activated Charcoal Arsenic Triiodide Oenanthe Aqua
- Multi-Component Preparation: Insufficient Data for Drug Repurposing Evaluation
Multi-Component Preparation: Insufficient Data for Drug Repurposing Evaluation
One-Sentence Summary
This candidate consists of a nine-ingredient mixture — including Activated Charcoal, Arsenic Triiodide, Oenanthe Aquatica Fruit, Oryctolagus Cuniculus Lung, Silicon Dioxide, Sulfur, Thyme, Tin, and Tribasic Calcium — with characteristics consistent with a homeopathic combination product. The TxGNN model was unable to generate any repurposing prediction for this candidate, as no DrugBank ID could be mapped and no original indications were registered in Taiwan. Without a valid prediction target, a standard repurposing evaluation cannot proceed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on record |
| Predicted New Indication | None generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A (No prediction generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Unavailable?
The TxGNN pipeline relies on mapping each drug’s active ingredient to a DrugBank node in the knowledge graph. For this candidate, no DrugBank ID was successfully assigned (drugbank_id: null), which prevents the model from locating the compound within the graph and computing traversal-based repurposing scores.
The ingredient list points toward a homeopathic combination product. Homeopathic preparations are typically not catalogued as discrete entities in DrugBank because their active fractions are defined by dilution series rather than by molecular structure. As a result, standard SMILES-based or target-based lookups return no match, and the deep-learning prediction pathway is also blocked.
Currently, detailed mechanism of action data is unavailable. Without a clear pharmacological target or established efficacy evidence in any approved indication, the mechanistic rationale for any new indication cannot be assessed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No US approvals (NDAs) on record for this candidate.
Safety Considerations
Please refer to the package insert for safety information.
Note — Arsenic Triiodide component: Although this mixture is presumed homeopathic (ultra-dilute), the nominal presence of arsenic triiodide warrants flagging. In pharmaceutical concentrations, arsenic-containing compounds carry significant toxicity (hepatotoxicity, cardiotoxicity, QTc prolongation). If this product is ever reformulated or evaluated at non-homeopathic concentrations, a full arsenic-specific safety assessment will be mandatory.
Conclusion and Next Steps
Decision: Hold
Rationale: TxGNN could not map this multi-ingredient candidate to the knowledge graph, so no repurposing prediction was generated; without a target indication, the evaluation pipeline cannot advance beyond this point.
To proceed, the following is needed:
- DrugBank ID resolution: Attempt per-ingredient lookups for each of the nine components individually (e.g., Arsenious acid → DB01169 for arsenic trioxide; Silicea → separate search) to determine whether any single ingredient can anchor a prediction.
- Original indication clarification: Identify the product’s approved or traditional use (likely a respiratory or detoxification indication for homeopathic preparations of this type) to establish a baseline for comparison.
- Regulatory classification: Confirm whether the product is classified as a homeopathic medicine, traditional herbal product, or conventional pharmaceutical in the target jurisdiction, as this determines which regulatory and safety frameworks apply.
- MOA documentation: If individual ingredients are pursued, document their pharmacological mechanisms before initiating any repurposing analysis.
- Safety dossier: Obtain the full prescribing information (especially for the arsenic triiodide fraction) before any clinical or preclinical forward planning.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.